Mi az ára Renascience Inc. (4889)

Renascience Inc. (4889) ára $8.49

Mi a Renascience Inc. (4889 piaci tőkésítése)

Renascience Inc. piaci tőkésítése (4889) $117.03M

Renascience Inc. (4889) Nyereség

Renascience Inc., established in 2000 and based in Tokyo, Japan, is actively engaged in pioneering and bringing to market pharmaceuticals and medical devices throughout Japan. The company's pipeline includes RS5614, a PAI-1 inhibitor that has reached Phase 3 clinical trials for a wide range of indications such as chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets. Another PAI-1 inhibitor, RS5441, is currently in Phase 1 trials for various dermatological conditions. Additionally, RS8001, a water-soluble vitamin, is undergoing Phase 2 clinical development for the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder. Beyond its pharmaceutical ventures, Renascience is also advancing the RS9001 disposable ultrafine endoscope, alongside developing artificial intelligence-driven medical solutions and comprehensive diagnostic tools.

Év	Nyereség	Változtassa meg
Nincs elég adat a megadott dátumokhoz.

Év

Nyereség

Változtassa meg

Nincs elég adat a megadott dátumokhoz.

Vállalat	Nyereség	Nyereségkülönbség	Ország
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
Moderna, Inc. MRNA.US	$-3.09B	-	US
CSL Limited CSL.AX	$-4.02B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Vállalat

Nyereség

Nyereségkülönbség

Ország